Charles River Laboratories Intl. (NYSE:CRL) is scheduled to be releasing its earnings data before the market opens on Wednesday, November 7th. Analysts expect Charles River Laboratories Intl. to post earnings of $1.38 per share for the quarter. Charles River Laboratories Intl. has set its FY18 guidance at $5.85-6.00 EPS.Persons interested in participating in the company’s earnings conference call can do so using this link.
Charles River Laboratories Intl. (NYSE:CRL) last issued its earnings results on Wednesday, August 8th. The medical research company reported $1.62 earnings per share for the quarter, topping the consensus estimate of $1.46 by $0.16. The company had revenue of $585.30 million during the quarter, compared to the consensus estimate of $570.65 million. Charles River Laboratories Intl. had a net margin of 6.38% and a return on equity of 25.26%. Charles River Laboratories Intl.’s quarterly revenue was up 24.8% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.29 EPS. On average, analysts expect Charles River Laboratories Intl. to post $6 EPS for the current fiscal year and $6 EPS for the next fiscal year.
Shares of Charles River Laboratories Intl. stock opened at $118.16 on Wednesday. The firm has a market capitalization of $5.68 billion, a P/E ratio of 22.41, a PEG ratio of 1.48 and a beta of 0.65. The company has a quick ratio of 1.48, a current ratio of 1.72 and a debt-to-equity ratio of 1.52. Charles River Laboratories Intl. has a fifty-two week low of $96.70 and a fifty-two week high of $135.90.
In other Charles River Laboratories Intl. news, insider David Ross Smith sold 1,249 shares of the business’s stock in a transaction on Monday, August 13th. The shares were sold at an average price of $120.05, for a total value of $149,942.45. Following the sale, the insider now owns 13,690 shares in the company, valued at approximately $1,643,484.50. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Deborah Turner Kochevar sold 4,066 shares of the business’s stock in a transaction on Tuesday, September 4th. The stock was sold at an average price of $123.66, for a total transaction of $502,801.56. Following the completion of the sale, the director now owns 10,190 shares in the company, valued at approximately $1,260,095.40. The disclosure for this sale can be found here. 2.10% of the stock is owned by insiders.
About Charles River Laboratories Intl.
Charles River Laboratories International, Inc, an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services worldwide. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing).
Further Reading: Book Value Per Share – BVPS
Receive News & Ratings for Charles River Laboratories Intl. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories Intl. and related companies with MarketBeat.com's FREE daily email newsletter.